Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-956-5 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study performed under GLP. All relevant validity criteria were met.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- inspected: July 2012; signature: November 2012
- Type of assay:
- bacterial reverse mutation assay
Test material
- Reference substance name:
- Reaction mass of (3E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one and 4-(dodecylsulfanyl)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-one and 4-(dodecylsulfanyl)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)butan-2-one
- EC Number:
- 700-956-5
- Molecular formula:
- not applicable (reaction mass of constitutional isomers)
- IUPAC Name:
- Reaction mass of (3E)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)but-3-en-2-one and 4-(dodecylsulfanyl)-4-(2,6,6-trimethylcyclohex-1-en-1-yl)butan-2-one and 4-(dodecylsulfanyl)-4-(2,6,6-trimethylcyclohex-2-en-1-yl)butan-2-one
- Test material form:
- gas under pressure: refrigerated liquefied gas
- Details on test material:
- - Physical state: liquid
- Storage condition of test material: Approximately 4°C in the dark under nitrogen.
- Other: Pale yellow
Constituent 1
Method
Species / strainopen allclose all
- Species / strain / cell type:
- E. coli WP2 uvr A
- Additional strain / cell type characteristics:
- not applicable
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- Rat liver S9
- Test concentrations with justification for top dose:
- - Preliminary toxicity test: 0, 0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 μg/plate
- Experiment 1 range-finding test (plate incorporation method): 0 (solvent control), 5, 15, 50, 150, 500, 1500 and 5000 μg/plate
- Experiment 2 (pre-incubation method):
Salmonella strains and E.coli strain with and without S9-mix: 0 (solvent control), 5, 15, 50, 150, 500, 1500 and 5000 μg/plate
Up to sevent test item dose levels were selected in Experiment 2 in order to achieve both a minimum of four non-toxic doses and the toxic limit of the test item following the change in test methodology. - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Acetone
- Justification for choice of solvent/vehicle: The test item was immiscible in sterile distilled water and dimethyl sulphoxide at 50 mg/ml but was fully miscible in acetone at 100 mg/ml in solubility checks performed. Acetone was therefore selected as the vehicle.
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- benzo(a)pyrene
- other: 2-Aminoanthracene
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: Experiment 1. in medium; in agar (plate incorporation) ; Experiment 2. in medium; in agar (pre-incubation)
DURATION
- Exposure duration:
Experiment 1. All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system.
Experiment 2. Measured aliquots (0.1 ml) of one of the bacterial cultures followed by 0.5 ml of S9-mix or phosphate buffer and 0.05 ml of the vehicle or test item formulation and incubated for 20 minutes at 37°C with shaking at approximately 130 rpm prior to the addition of 2 ml of molten amino acid supplemented, top agar. Subsequently, the procedure for incubation and duration was the same as in Experiment 1.
NUMBER OF REPLICATIONS: 3
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
5. Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response).
A test item is considered non-mutagenic (negative) in the test system if the above criteria are not met.
In instances of data prohibiting definitive judgement about test item activity are reported as equivocal. - Statistics:
- Statistical methods (Mahon, et al.); as recommended by the UKEMS Subcommittee on Guidelines for Mutagenicity Testing, Report - Part III (1989).
Results and discussion
Test resultsopen allclose all
- Species / strain:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
Any other information on results incl. tables
Table 1 : Test Results: Range-finding test: Experiment 1 with and without metabolic activation and results of concurrent positive controls
|
|||||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|||||||||||
Base-pair substitution strains |
Frameshift strains |
||||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|||||||||
Solvent Control (Acetone) |
95 (100) 114 12.7# 90 |
17 (15) 17 2.9 12 |
33 (36) 41 4.2 35 |
32 (26) 27 6.6 19 |
15 (11) 7 4.0 12 |
||||||||
5 µg |
96 (94) 92 2.1 95 |
19 (17) 18 2.1 15 |
33 (36) 39 3.1 37 |
26 (21) 17 4.7 19 |
17 (13) 12 3.2 11 |
||||||||
15 µg |
91 (101) 101 10.5 112 |
12 (11) 13 2.1 9 |
35 (37) 37 1.5 38 |
22 (24) 24 2.0 26 |
9 (9) 8 0.6 9 |
||||||||
50 µg |
81 (90) 79 17.9 111 |
19 (16) 18 4.4 11 |
38 (31) 24 7.0 31 |
25 (21) 20 3.6 18 |
11 (13) 11 2.9 16 |
||||||||
150 µg |
91 (90) 82 7.1 96 |
11 (14) 15 3.1 17 |
29 (28) 28 0.6 28 |
19 (17) 16 2.1 15 |
14 (11) 12 3.6 7 |
||||||||
500 µg |
90 (102) 108 10.7 109 |
14 (14) 13 0.6 14 |
37 (32) 31 5.0 27 |
17 (20) 21 2.3 21 |
8 (9) 11 2.1 7 |
||||||||
1500 µg |
96 TP (100) 89 TP 14.0 116 TP |
17 TP (17) 18 TP 1.5 15 TP |
29 P (30) 29 P 1.7 32 P |
35 P (24) 11 P 12.1 25 P |
7 TP (7) 7 TP 0.6 6 TP |
||||||||
5000 µg |
84 TP (56) 59 TP 30.1 24 TP |
6 TP (9) 7 TP 3.8 13 TP |
28 TP (36) 35 TP 8.0 44 TP |
16 TP (17) 19 TP 1.5 17 TP |
6 TP (6) 5 TP 0.6 6 TP |
||||||||
Positive controls S9-Mix (-) |
Name |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
|||||||
Dose |
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
||||||||
Level No. of Revertants |
851 (702) 616 129.5 639 |
626 (555) 462 84.2 577 |
1155 (1031) 1068 146.6 869 |
180 (190) 184 14.6 207 |
1096 (846) 696 217.7 747 |
||||||||
|
|
||||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|
||||||||||
Base-pair substitution strains |
Frameshift strains |
|
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|
||||||||
Solvent Control (Acetone) |
116 (106) 102 8.4# 101 |
16 (15) 10 5.0 20 |
38 (35) 36 3.6 31 |
37 (35) 39 5.9 28 |
11 (10) 12 2.1 8 |
|
|||||||
5 µg |
110 (105) 103 4.4 102 |
13 (13) 11 1.5 14 |
30 (30) 30 0.6 31 |
28 (27) 26 1.2 26 |
7 (8) 10 2.1 6 |
|
|||||||
15 µg |
86 (100) 111 12.8 103 |
16 (14) 8 4.9 17 |
38 (36) 34 2.0 36 |
16 (20) 16 6.4 27 |
12 (12) 12 0.6 11 |
|
|||||||
50 µg |
101 (98) 103 7.6 89 |
9 (11) 13 2.1 12 |
33 (35) 44 8.6 27 |
29 (26) 26 2.5 24 |
9 (9) 7 2.0 11 |
|
|||||||
150 µg |
103 (110) 123 11.0 105 |
13 (12) 13 1.2 11 |
35 (36) 35 1.2 37 |
22 (25) 30 4.6 22 |
12 (11) 12 1.7 9 |
|
|||||||
500 µg |
122 (101) 71 26.8 111 |
14 (13) 9 3.2 15 |
42 (38) 40 4.7 33 |
32 (32) 32 0.6 33 |
6 (9) 10 2.3 10 |
|
|||||||
1500 µg |
119 TP (110) 111 TP 9.5 100 TP |
11 TP (13) 17 TP 3.8 10 TP |
29 P (36) 39 P 5.8 39 P |
32 P (32) 29 P 3.5 36 P |
10 P (10) 10 P 0.0 10 P |
|
|||||||
5000 µg |
94 TP (91) 95 TP 6.7 83 TP |
10 TP (12) 13 TP 1.7 13 TP |
38 TP (37) 38 TP 2.3 34 TP |
30 P (31) 34 P 2.6 29 P |
18 TP (11) 8 TP 5.8 8 TP |
|
|||||||
Positive controls S9-Mix (+) |
Name |
2AA |
2AA |
2AA |
BP |
2AA |
|
||||||
Dose |
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
|
|||||||
Level No. of Revertants |
1376 (1533) 1484 186.4 1739 |
274 (259) 249 13.4 253 |
334 (377) 440 55.6 358 |
269 (283) 285 12.7 294 |
301 (243) 182 59.5 245 |
|
|||||||
ENNG: N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO: 4-Nitroquinoline-1-oxide
9AA: 9-AminoacridineENNG:
BP: Benzo(a)pyrene
2AA: 2-Aminoanthracene
T: Partial absence of bacterial background lawn
P: Precipitate
#: Standard deviation
Table 2 : Test Results: Experiment 2 with and without metabolic activation and results of concurrent positive controls
|
||||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
||||||||
Solvent Control (Acetone) |
115 (120) 123 4.6# 123 |
21 (22) 24 2.1 20 |
24 (33) 42 9.0 33 |
19 (25) 21 8.7 35 |
10 (11) 16 4.2 8 |
|||||||
5 µg |
104 (116) 105 19.9 139 |
16 (18) 18 2.5 21 |
28 (27) 25 1.7 28 |
18 (16) 16 2.5 13 |
4 (7) 9 2.5 7 |
|||||||
15 µg |
134 (107) 68 34.6 119 |
18 (20) 20 2.0 22 |
25 (31) 36 5.7 33 |
15 (21) 20 6.0 27 |
9 (12) 16 3.8 10 |
|||||||
50 µg |
100 (99) 98 1.2 100 |
17 (17) 18 0.6 17 |
25 (28) 31 3.1 29 |
19 (18) 17 1.2 19 |
10 (12) 15 2.6 11 |
|||||||
150 µg |
99 (106) 108 6.7 112 |
17 (20) 19 3.6 24 |
25 (31) 37 6.0 31 |
13 (19) 27 7.4 16 |
10 (11) 15 4.0 7 |
|||||||
500 µg |
123 (121) 132 11.6 109 |
16 (17) 20 2.3 16 |
19 (25) 29 5.5 28 |
25 (25) 26 1.0 24 |
13 T (10) 10 T 3.5 6 T |
|||||||
1500 µg |
124 TP (110) 108 TP 13.6 97 TP |
22 TP (15) 9 TP 6.5 15 TP |
46 P (33) 27 P 11.3 26 P |
15 TP (15) 17 TP 2.0 13 TP |
10 TP (10) 10 TP 0.6 11 TP |
|||||||
5000 µg |
118 TP (100) 98 TP 16.6 85 TP |
16 TP (12) 9 TP 3.5 12 TP |
30 TP (26) 28 TP 4.7 21 TP |
18 TP (16) 16 TP 2.5 13 TP |
3 TP (4) 5 TP 1.2 3 TP |
|||||||
Positive controls S9-Mix (-) |
Name |
ENNG |
ENNG |
ENNG |
4NQO |
9AA |
||||||
Dose |
3 µg |
5 µg |
2 µg |
0.2 µg |
80 µg |
|||||||
Level No. of Revertants |
589 (607) 627 19.1 605 |
581 (544) 526 32.0 525 |
593 (649) 695 51.8 660 |
129 (137) 147 9.3 134 |
344 (507) 646 152.5 532 |
|||||||
|
|
|||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
|
|||||||||
Base-pair substitution strains |
Frameshift strains |
|
||||||||||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
|
|||||||
Solvent Control (Acetone) |
77 (85) 72 17.8# 105 |
20 (14) 13 6.0 8 |
30 (32) 32 2.0 34 |
22 (26) 31 4.6 25 |
8 (12) 14 3.2 13 |
|
||||||
5 µg |
92 (86) 90 8.7 76 |
16 (12) 9 3.8 10 |
36 (38) 44 4.9 35 |
25 (27) 30 2.9 25 |
13 (12) 7 4.2 15 |
|
||||||
15 µg |
86 (87) 82 5.6 93 |
11 (9) 9 1.5 8 |
31 (31) 31 0.6 30 |
26 (23) 26 4.6 18 |
18 (13) 12 4.2 10 |
|
||||||
50 µg |
95 (96) 96 1.5 98 |
10 (9) 9 1.0 8 |
32 (31) 25 5.1 35 |
24 (30) 31 6.0 36 |
10 (13) 16 3.1 12 |
|
||||||
150 µg |
101 (87) 89 14.6 72 |
11 (14) 15 2.3 15 |
26 (32) 32 5.5 37 |
26 (26) 21 5.0 31 |
13 (12) 10 2.1 14 |
|
||||||
500 µg |
74 (72) 63 8.6 80 |
11 (12) 11 2.3 15 |
34 (39) 40 4.2 42 |
21 (22) 32 9.1 14 |
16 T (11) 10 T 4.6 7 T |
|
||||||
1500 µg |
81 TP (78) 75 TP 3.1 77 TP |
13 TP (11) 8 TP 2.5 11 TP |
29 P (32) 34 P 2.9 34 P |
25 P (23) 16 P 6.2 28 P |
12 TP (10) 8 TP 2.0 10 TP |
|
||||||
5000 µg |
61 TP (68) 69 TP 7.0 75 TP |
9 TP (9) 9 TP 0.6 8 TP |
31 TP (35) 33 TP 5.9 42 TP |
24 TP (19) 17 TP 4.0 17 TP |
8 TP (10) 14 TP 3.5 8 TP |
|
||||||
Positive controls S9-Mix (+) |
Name |
2AA |
2AA |
2AA |
BP |
2AA |
|
|||||
Dose |
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
|
||||||
Level No. of Revertants |
849 (736) 653 101.2 707 |
201 (193) 179 12.2 199 |
346 (325) 334 26.1 296 |
227 (252) 255 24.1 275 |
167 (174) 185 9.6 170 |
|
||||||
ENNG: N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO: 4-Nitroquinoline-1-oxide
9AA: 9-AminoacridineENNG:
BP: Benzo(a)pyrene
2AA: 2-Aminoanthracene
T: Partial absence of bacterial background lawn
P: Precipitate
#: Standard deviation
Table 3. Spontaneous Mutation Rates (Concurrent Negative Controls)
Range-finding test: EXP1 |
||||
Number of revertants (mean number of colonies per plate) |
||||
Base-pair substitution type |
Frameshift type |
|||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
83 94 (91) 97 |
17 13 (19) 27 |
28 29 (32) 38 |
15 25 (22) 26 |
7 4 (7) 10 |
Main test: EXP2 |
||||
Number of revertants (mean number of colonies per plate) |
||||
Base-pair substitution type |
Frameshift type |
|||
TA100 |
TA1535 |
WP2uvrA |
TA98 |
TA1537 |
125 109 (114) 108 |
25 20 (21) 17 |
33 40 (36) 35 |
26 22 (24) 25 |
9 8 (9) 10 |
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results:
negative
Under the conditions of this study the test material was considered to be non-mutagenic in the presence and absence of S9 activation. - Executive summary:
The study was performed to the requirements of OECD Guideline 471, EU Method B13/14, US EPA OPPT 870.5100 and Japanese guidelines for bacterial mutagenicity testing under GLP, to evaluate the potential mutagenicity of the test substance in a bacterial reverse mutation assay using S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA- in both the presence and absence of S-9 mix. The test strains were treated with the test substance using both the Ames plate incorporation and pre incubation methods at up to seven dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). The dose range for the range-finding test was determined in a preliminary toxicity assay and was 5 to 5000 μg/plate. The experiment was repeated on a separate day (pre-incubation method) using the same dose range, fresh cultures of the bacterial strains and fresh test item formulations. Additional dose levels and an expanded dose range were selected in both experiments in order to achieve four non-toxic dose levels and the toxic limit of the test item. The vehicle (acetone) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. In the range-finding test (plate incorporation method) the test item caused a visible reduction in the growth of the bacterial background lawns of all of the tester strains (except TA98 dosed in the presence of S9-mix), initially from 1500 μg/plate in both the presence and absence of S9-mix. In the main test (pre-incubation method) the test item induced toxicity to all of the tester strains with Salmonella strain TA1537 exhibiting weakened lawns from 500 μg/plate in both the absence and presence of S9-mix. These results were not indicative of toxicity sufficiently severe enough to prevent the test item being tested up to the maximum recommended dose level of 5000 μg/plate. A test item precipitate (globular in appearance) was noted at and above 1500 μg/plate, this observation did not prevent the scoring of revertant colonies. No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation or exposure method. It was concluded that, under the conditions of this assay, the test substance gave a negative, i.e. non-mutagenic response in S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2uvrA in the presence and absence of S-9 mix.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.